Standout Papers

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory S... 2007 2026 2013 2019 2.3k
  1. Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates (2010)
    Julie R. Brahmer, Charles G. Drake et al. Journal of Clinical Oncology
  2. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy (2016)
    Suzanne L. Topalian, Janis M. Taube et al. Nature reviews. Cancer
  3. Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy (2014)
    Janis M. Taube, Alison Klein et al. Clinical Cancer Research
  4. Elucidation of a Universal Size-Control Mechanism in Drosophila and Mammals (2007)
    Jixin Dong, Georg Feldmann et al. Cell
  5. Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape (2012)
    Janis M. Taube, Robert A. Anders et al. Science Translational Medicine
  6. Genetic and pharmacological disruption of the TEAD–YAP complex suppresses the oncogenic activity of YAP (2012)
    Yi Liu‐Chittenden, Bo Huang et al. Genes & Development
  7. The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints (2014)
    Nicolás J. Llosa, Michael Cruise et al. Cancer Discovery
  8. Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria (2018)
    Christine M. Dejea, Payam Fathi et al. Science
  9. The Merlin/NF2 Tumor Suppressor Functions through the YAP Oncoprotein to Regulate Tissue Homeostasis in Mammals (2010)
    Nailing Zhang, Haibo Bai et al. Developmental Cell
  10. A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer (2017)
    David L. Rimm, Gang Han et al. JAMA Oncology
  11. Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade (2019)
    Steve Lu, Julie E. Stein et al. JAMA Oncology
  12. Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma (2016)
    Elizabeth D. Thompson, Marianna Zahurak et al. Gut
  13. PD-1 blockade in tumors with mismatch repair deficiency. (2015)
    Dung T. Le, Jennifer N. Uram et al. Journal of Clinical Oncology

Immediate Impact

12 by Nobel laureates 38 from Science/Nature 183 standout
Sub-graph 1 of 15

Citing Papers

Neuronal substance P drives metastasis through an extracellular RNA–TLR7 axis
2024 StandoutNature
SOX17 enables immune evasion of early colorectal adenomas and cancers
2024 StandoutNature

Works of Robert A. Anders being referenced

Axon Guidance Molecules Promote Perineural Invasion and Metastasis of Orthotopic Pancreatic Tumors in Mice
2019
The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints
2014 Standout

Author Peers

Author Last Decade Papers Cites
Robert A. Anders 15692 3634 7741 8410 269 27.9k
Harold L. Moses 14456 3181 24171 4843 311 40.1k
David A. Tuveson 20810 4869 19285 7359 200 40.1k
Setsuo Hirohashi 8598 3878 15216 2607 441 28.1k
Eric G. Neilson 5673 3801 13586 3388 202 29.0k
Robert S. Kerbel 16351 1661 24243 5451 398 41.1k
Zvi Fuks 5215 4064 10573 2822 403 31.5k
Jörg Kleeff 14061 6215 8530 2632 415 22.7k
Robert Rosenberg 6786 5570 9505 2383 415 31.5k
Ming‐Sound Tsao 14968 2938 16214 2822 644 36.3k
Amato J. Giaccia 10629 2112 22859 4509 346 39.7k

All Works

Loading papers...

Rankless by CCL
2026